Skip to main content

Table 3 Sensitivity analyses of virological failure definition

From: The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data

 

Default

Sensitivity 1

Sensitivity 3

VF ≥ 200 cps/mL

VF ≥ 200 cps/mL

VF ≥ 1,000 cps/mL

VF ≥ 10,000 cps/mL

Multivariable HR (95% CI)

p-value

Multivariable HR (95% CI)

p-value

Multivariable HR (95% CI)

p-value

Multivariable HR (95% CI)

p-value

Monitoring randomisation

 LCM

1.00

-

1.00

-

1.00

-

1.00

-

 CDM

1.11 (0.93 – 1.34)

0.25

1.16 (0.98 – 1.38)

0.09

1.14 (0.94 – 1.37)

0.19

1.18 (0.96 – 1.45)

0.11

Gender

 Male

1.00

-

1.00

-

1.00

-

1.00

-

 Female

0.79 (0.65 – 0.95)

0.01

0.84 (0.70 – 1.01)

0.06

0.78 (0.64 – 0.95)

0.01

0.77 (0.62 – 0.95)

0.02

Initial ART

 TDF

1.00

<0.0001

1.00

<0.0001

1.00

<0.0001

1.00

<0.0001

 NVP

0.48 (0.38 – 0.62)

-

0.49 (0.39 – 0.62)

-

0.49 (0.38 – 0.63)

-

0.50 (0.38 – 0.65)

-

 ABC

1.27 (1.02 – 1.59)

-

1.23 (0.99 – 1.52)

-

1.23 (0.97 – 1.55)

-

1.00 (0.76 – 1.31)

-

TB in 12 months prior to enrolment

1.07 (0.86 – 1.33)

0.52

1.07 (0.88 – 1.32)

0.47

1.08 (0.86 – 1.36)

0.49

1.15 (0.91 – 1.46)

0.24

Age (per 10 years older)

0.73 (0.64 – 0.84)

<0.0001

0.77 (0.68 – 0.88)

<0.0001

0.70 (0.61 – 0.81)

<0.0001

0.69 (0.60 – 0.80)

<0.0001

Baseline CD4 (per 100 cells/mm3 higher)

0.64 (0.54 – 0.75)

<0.0001

0.67 (0.57 – 0.78)

<0.0001

0.60 (0.50 – 0.72)

<0.0001

0.52 (0.43 – 0.64)

<0.0001

Baseline viral load (log10 copies/mL)

1.01 (0.84 – 1.22)

0.89

0.99 (0.83 – 1.18)

0.91

1.02 (0.84 – 1.24)

0.82

1.02 (0.82 – 1.25)

0.88

Adherence in previous 48 weeksa (per 10% higher)

0.89 (0.84 – 0.94)

<0.0001

0.90 (0.85 – 0.94)

<0.0001

0.89 (0.84 – 0.94)

<0.0001

0.88 (0.82 – 0.94)

<0.0001

  1. atime-updated